Praxis has reached a major regulatory inflection point, with relutrigine and ulixacaltamide under active FDA review and company-reported mid-cycle meetings identifying no major safety or efficacy concerns to date. Ulixacaltamide is supported by positive pivotal Essential3 studies, while relutrigine addresses severe SCN2A and SCN8A developmental and epileptic encephalopathies. Elsunersen adds differentiated pipeline optionality after a 77% sham-adjusted seizure reduction in EMBRAVE Part A and receipt of Breakthrough Therapy Designation. These merits are balanced by concentrated binary regulatory risk, the three-month relutrigine review extension following a major amendment, launch-execution uncertainty, and the POWER1 primary-endpoint miss that weakened the vormatrigine program.